$IMVT
Immunovant, Inc.

2023 Q1 Form 10-Q Financial Statement

#000176401323000022 Filed on February 03, 2023

View on sec.gov

Income Statement

Concept 2023 Q1 2022 Q4
Revenue $0.00 $0.00
YoY Change
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin $12.42M $11.78M
YoY Change -18.5% 2.26%
% of Gross Profit
Research & Development $51.84M $42.25M
YoY Change 62.06% 41.99%
% of Gross Profit
Depreciation & Amortization $54.00K $49.00K
YoY Change 38.46% 48.48%
% of Gross Profit
Operating Expenses $64.26M $64.03M
YoY Change 36.06% 55.14%
Operating Profit
YoY Change
Interest Expense $3.480M $2.944M
YoY Change
% of Operating Profit
Other Income/Expense, Net $356.0K -$1.757M
YoY Change 709.09% 1441.23%
Pretax Income -$60.42M -$62.84M
YoY Change 28.06% 51.84%
Income Tax -$991.0K $387.0K
% Of Pretax Income
Net Earnings -$59.43M -$63.23M
YoY Change 25.99% 52.78%
Net Earnings / Revenue
Basic Earnings Per Share -$0.49
Diluted Earnings Per Share -$0.46 -$0.49
COMMON SHARES
Basic Shares Outstanding 130.2M shares 129.2M shares
Diluted Shares Outstanding 128.6M shares

Balance Sheet

Concept 2023 Q1 2022 Q4
SHORT-TERM ASSETS
Cash & Short-Term Investments $376.5M $432.6M
YoY Change -23.75% -17.91%
Cash & Equivalents $376.5M $432.6M
Short-Term Investments
Other Short-Term Assets $26.92M $21.11M
YoY Change 330.45% 56.64%
Inventory
Prepaid Expenses $26.92M $21.11M
Receivables $700.0K $704.0K
Other Receivables $185.0K $0.00
Total Short-Term Assets $404.3M $454.4M
YoY Change -21.17% -15.92%
LONG-TERM ASSETS
Property, Plant & Equipment $333.0K $362.0K
YoY Change 0.91% 44.8%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets
YoY Change
Total Long-Term Assets $1.505M $1.821M
YoY Change -42.84% -32.61%
TOTAL ASSETS
Total Short-Term Assets $404.3M $454.4M
Total Long-Term Assets $1.505M $1.821M
Total Assets $405.8M $456.2M
YoY Change -21.28% -16.01%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $1.353M $14.00M
YoY Change -92.74% 265.93%
Accrued Expenses $40.42M $26.05M
YoY Change 63.34% -17.16%
Deferred Revenue
YoY Change
Short-Term Debt $0.00 $0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities $43.30M $41.26M
YoY Change -2.75% 13.49%
LONG-TERM LIABILITIES
Long-Term Debt $0.00 $0.00
YoY Change
Other Long-Term Liabilities $47.00K $306.0K
YoY Change -96.14% -81.79%
Total Long-Term Liabilities $47.00K $306.0K
YoY Change -96.14% -81.79%
TOTAL LIABILITIES
Total Short-Term Liabilities $43.30M $41.26M
Total Long-Term Liabilities $47.00K $306.0K
Total Liabilities $43.34M $41.57M
YoY Change -5.24% 9.28%
SHAREHOLDERS EQUITY
Retained Earnings -$566.3M -$506.9M
YoY Change 59.35% 64.47%
Common Stock $13.00K $13.00K
YoY Change 8.33% 8.33%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $362.5M $414.7M
YoY Change
Total Liabilities & Shareholders Equity $405.8M $456.2M
YoY Change -21.28% -16.01%

Cashflow Statement

Concept 2023 Q1 2022 Q4
OPERATING ACTIVITIES
Net Income -$59.43M -$63.23M
YoY Change 25.99% 52.78%
Depreciation, Depletion And Amortization $54.00K $49.00K
YoY Change 38.46% 48.48%
Cash From Operating Activities -$55.79M -$46.40M
YoY Change 69.3% 45.46%
INVESTING ACTIVITIES
Capital Expenditures $26.00K $98.00K
YoY Change -122.03% -232.43%
Acquisitions
YoY Change
Other Investing Activities
YoY Change
Cash From Investing Activities -$26.00K -$98.00K
YoY Change -77.97% 32.43%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities 233.0K 70.63M
YoY Change
NET CHANGE
Cash From Operating Activities -55.79M -46.40M
Cash From Investing Activities -26.00K -98.00K
Cash From Financing Activities 233.0K 70.63M
Net Change In Cash -55.59M 24.14M
YoY Change 68.07% -175.5%
FREE CASH FLOW
Cash From Operating Activities -$55.79M -$46.40M
Capital Expenditures $26.00K $98.00K
Free Cash Flow -$55.82M -$46.49M
YoY Change 69.98% 46.11%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
dei Entity Central Index Key
EntityCentralIndexKey
0001764013
dei Amendment Flag
AmendmentFlag
false
dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--03-31
dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
Q3
dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2023
dei Document Type
DocumentType
10-Q
dei Document Quarterly Report
DocumentQuarterlyReport
true
dei Document Period End Date
DocumentPeriodEndDate
2022-12-31
dei Document Transition Report
DocumentTransitionReport
false
dei Entity File Number
EntityFileNumber
001-38906
dei Entity Registrant Name
EntityRegistrantName
IMMUNOVANT, INC.
dei Entity Incorporation State Country Code
EntityIncorporationStateCountryCode
DE
dei Entity Tax Identification Number
EntityTaxIdentificationNumber
83-2771572
dei Entity Address Address Line1
EntityAddressAddressLine1
320 West 37th Street
dei Entity Address Postal Zip Code
EntityAddressPostalZipCode
10018
dei Entity Address City Or Town
EntityAddressCityOrTown
New York,
dei Entity Address State Or Province
EntityAddressStateOrProvince
NY
dei City Area Code
CityAreaCode
917
dei Local Phone Number
LocalPhoneNumber
580-3099
dei Security12b Title
Security12bTitle
Common Stock, $0.0001 par value per share
dei Trading Symbol
TradingSymbol
IMVT
dei Security Exchange Name
SecurityExchangeName
NASDAQ
dei Entity Current Reporting Status
EntityCurrentReportingStatus
Yes
dei Entity Interactive Data Current
EntityInteractiveDataCurrent
Yes
dei Entity Filer Category
EntityFilerCategory
Non-accelerated Filer
dei Entity Small Business
EntitySmallBusiness
true
dei Entity Emerging Growth Company
EntityEmergingGrowthCompany
false
dei Entity Shell Company
EntityShellCompany
false
CY2023Q1 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
130245335 shares
CY2022Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
432608000 usd
CY2022Q1 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
493817000 usd
CY2022Q4 us-gaap Accounts Receivable Net Current
AccountsReceivableNetCurrent
704000 usd
CY2022Q1 us-gaap Accounts Receivable Net Current
AccountsReceivableNetCurrent
12229000 usd
CY2022Q4 us-gaap Prepaid Expense Current
PrepaidExpenseCurrent
21110000 usd
CY2022Q1 us-gaap Prepaid Expense Current
PrepaidExpenseCurrent
6885000 usd
CY2022Q4 us-gaap Assets Current
AssetsCurrent
454422000 usd
CY2022Q1 us-gaap Assets Current
AssetsCurrent
512931000 usd
CY2022Q4 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
1459000 usd
CY2022Q1 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
2303000 usd
CY2022Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
362000 usd
CY2022Q1 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
330000 usd
CY2022Q4 us-gaap Assets
Assets
456243000 usd
CY2022Q1 us-gaap Assets
Assets
515564000 usd
us-gaap Effective Income Tax Rate Continuing Operations
EffectiveIncomeTaxRateContinuingOperations
-0.0066
CY2022Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
14004000 usd
CY2022Q1 us-gaap Accounts Payable Current
AccountsPayableCurrent
18629000 usd
CY2022Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
26050000 usd
CY2022Q1 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
24746000 usd
CY2022Q4 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
1205000 usd
CY2022Q1 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
1145000 usd
CY2022Q4 us-gaap Liabilities Current
LiabilitiesCurrent
41259000 usd
CY2022Q1 us-gaap Liabilities Current
LiabilitiesCurrent
44520000 usd
CY2022Q4 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
306000 usd
CY2022Q1 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
1219000 usd
CY2022Q4 us-gaap Liabilities
Liabilities
41565000 usd
CY2022Q1 us-gaap Liabilities
Liabilities
45739000 usd
CY2022Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
usd
CY2022Q1 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
usd
CY2022Q1 us-gaap Common Stock No Par Value
CommonStockNoParValue
0.0001
us-gaap Share Based Compensation
ShareBasedCompensation
22381000 usd
CY2022Q4 us-gaap Common Stock No Par Value
CommonStockNoParValue
0.0001
CY2022Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
500000000 shares
CY2022Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
129260254 shares
CY2022Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
129260254 shares
CY2022Q1 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
500000000 shares
CY2022Q1 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
116482899 shares
CY2022Q1 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
116482899 shares
CY2022Q4 us-gaap Common Stock Value
CommonStockValue
13000 usd
CY2022Q1 us-gaap Common Stock Value
CommonStockValue
12000 usd
CY2022Q4 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
920197000 usd
CY2022Q1 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
824796000 usd
CY2022Q4 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
1383000 usd
CY2022Q1 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
404000 usd
CY2022Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-506915000 usd
CY2022Q1 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-355387000 usd
CY2022Q4 us-gaap Stockholders Equity
StockholdersEquity
414678000 usd
CY2022Q1 us-gaap Stockholders Equity
StockholdersEquity
469825000 usd
CY2022Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
456243000 usd
CY2022Q1 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
515564000 usd
CY2022Q4 us-gaap Research And Development Expense Excluding Acquired In Process Cost
ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost
42252000 usd
CY2021Q4 us-gaap Research And Development Expense Excluding Acquired In Process Cost
ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost
29756000 usd
us-gaap Research And Development Expense Excluding Acquired In Process Cost
ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost
108420000 usd
us-gaap Research And Development Expense Excluding Acquired In Process Cost
ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost
69822000 usd
CY2022Q4 us-gaap Research And Development In Process
ResearchAndDevelopmentInProcess
10000000 usd
CY2021Q4 us-gaap Research And Development In Process
ResearchAndDevelopmentInProcess
0 usd
us-gaap Research And Development In Process
ResearchAndDevelopmentInProcess
10000000 usd
us-gaap Research And Development In Process
ResearchAndDevelopmentInProcess
0 usd
CY2022Q4 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
11775000 usd
CY2021Q4 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
11515000 usd
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
35597000 usd
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
38984000 usd
CY2022Q4 us-gaap Operating Expenses
OperatingExpenses
64027000 usd
CY2021Q4 us-gaap Operating Expenses
OperatingExpenses
41271000 usd
us-gaap Operating Expenses
OperatingExpenses
154017000 usd
us-gaap Operating Expenses
OperatingExpenses
108806000 usd
CY2022Q4 us-gaap Interest Income Expense Net
InterestIncomeExpenseNet
2944000 usd
CY2021Q4 us-gaap Interest Income Expense Net
InterestIncomeExpenseNet
0 usd
us-gaap Interest Income Expense Net
InterestIncomeExpenseNet
4098000 usd
us-gaap Interest Income Expense Net
InterestIncomeExpenseNet
0 usd
CY2022Q4 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
-1757000 usd
CY2021Q4 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
-114000 usd
us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
-609000 usd
us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
-825000 usd
CY2022Q4 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-62840000 usd
CY2021Q4 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-41385000 usd
us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-150528000 usd
us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-109631000 usd
CY2022Q4 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
387000 usd
CY2021Q4 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
0 usd
us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
1000000 usd
us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
-72000 usd
CY2022Q4 us-gaap Net Income Loss
NetIncomeLoss
-63227000 usd
CY2021Q4 us-gaap Net Income Loss
NetIncomeLoss
-41385000 usd
us-gaap Net Income Loss
NetIncomeLoss
-151528000 usd
us-gaap Net Income Loss
NetIncomeLoss
-109559000 usd
CY2022Q4 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.49
CY2022Q4 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.49
CY2021Q4 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.36
CY2021Q4 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.36
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-1.26
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-1.26
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-1.02
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-1.02
us-gaap Related Party Transaction Amounts Of Transaction
RelatedPartyTransactionAmountsOfTransaction
300000 usd
CY2022Q4 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
128574190 shares
CY2022Q4 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
128574190 shares
CY2021Q4 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
115025191 shares
CY2021Q4 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
115025191 shares
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
120665299 shares
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
120665299 shares
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
107447745 shares
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
107447745 shares
CY2022Q4 us-gaap Net Income Loss
NetIncomeLoss
-63227000 usd
CY2021Q4 us-gaap Net Income Loss
NetIncomeLoss
-41385000 usd
us-gaap Net Income Loss
NetIncomeLoss
-151528000 usd
us-gaap Net Income Loss
NetIncomeLoss
-109559000 usd
CY2022Q4 us-gaap Other Comprehensive Income Foreign Currency Transaction And Translation Adjustment Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent
2620000 usd
CY2021Q4 us-gaap Other Comprehensive Income Foreign Currency Transaction And Translation Adjustment Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent
-23000 usd
us-gaap Other Comprehensive Income Foreign Currency Transaction And Translation Adjustment Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent
979000 usd
us-gaap Other Comprehensive Income Foreign Currency Transaction And Translation Adjustment Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent
717000 usd
CY2022Q4 us-gaap Other Comprehensive Income Loss Net Of Tax
OtherComprehensiveIncomeLossNetOfTax
2620000 usd
CY2021Q4 us-gaap Other Comprehensive Income Loss Net Of Tax
OtherComprehensiveIncomeLossNetOfTax
-23000 usd
us-gaap Other Comprehensive Income Loss Net Of Tax
OtherComprehensiveIncomeLossNetOfTax
979000 usd
us-gaap Other Comprehensive Income Loss Net Of Tax
OtherComprehensiveIncomeLossNetOfTax
717000 usd
CY2022Q4 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-60607000 usd
CY2021Q4 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-41408000 usd
us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-150549000 usd
us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-108842000 usd
CY2022Q1 us-gaap Stockholders Equity
StockholdersEquity
469825000 usd
CY2022Q2 imvt Stock Issued During Period Value Stock Options Exercised And Restricted Stock Award
StockIssuedDuringPeriodValueStockOptionsExercisedAndRestrictedStockAward
21000 usd
CY2022Q2 imvt Adjustments To Additional Paid In Capital Contribution Share Based Compensation
AdjustmentsToAdditionalPaidInCapitalContributionShareBasedCompensation
132000 usd
CY2022Q2 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
7555000 usd
CY2022Q2 us-gaap Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax
OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
-667000 usd
CY2022Q2 us-gaap Net Income Loss
NetIncomeLoss
-40373000 usd
CY2022Q2 us-gaap Stockholders Equity
StockholdersEquity
436493000 usd
CY2022Q3 imvt Adjustments To Additional Paid In Capital Contribution Share Based Compensation
AdjustmentsToAdditionalPaidInCapitalContributionShareBasedCompensation
106000 usd
CY2022Q3 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
8051000 usd
CY2022Q3 us-gaap Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax
OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
-974000 usd
CY2022Q3 us-gaap Net Income Loss
NetIncomeLoss
-47928000 usd
CY2022Q3 us-gaap Stockholders Equity
StockholdersEquity
395748000 usd
CY2022Q4 imvt Stock Issued During Period Value Stock Options Exercised And Restricted Stock Award
StockIssuedDuringPeriodValueStockOptionsExercisedAndRestrictedStockAward
403000 usd
CY2022Q4 imvt Adjustments To Additional Paid In Capital Contribution Share Based Compensation
AdjustmentsToAdditionalPaidInCapitalContributionShareBasedCompensation
50000 usd
CY2022Q4 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
8856000 usd
CY2022Q4 us-gaap Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax
OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
2620000 usd
CY2022Q4 us-gaap Net Income Loss
NetIncomeLoss
-63227000 usd
CY2022Q4 us-gaap Stockholders Equity
StockholdersEquity
414678000 usd
CY2021Q1 us-gaap Stockholders Equity
StockholdersEquity
391480000 usd
CY2021Q2 imvt Adjustments To Additional Paid In Capital Contribution Share Based Compensation
AdjustmentsToAdditionalPaidInCapitalContributionShareBasedCompensation
41000 usd
CY2021Q2 imvt Adjustments To Additional Paid In Capital Contribution Expenses Allocated From Related Party
AdjustmentsToAdditionalPaidInCapitalContributionExpensesAllocatedFromRelatedParty
91000 usd
CY2021Q2 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
3820000 usd
CY2021Q2 us-gaap Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax
OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
571000 usd
CY2021Q2 us-gaap Net Income Loss
NetIncomeLoss
-30471000 usd
CY2021Q2 us-gaap Stockholders Equity
StockholdersEquity
365532000 usd
CY2021Q3 us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
200000000 usd
CY2021Q3 imvt Adjustments To Additional Paid In Capital Contribution Share Based Compensation
AdjustmentsToAdditionalPaidInCapitalContributionShareBasedCompensation
692000 usd
CY2021Q3 imvt Adjustments To Additional Paid In Capital Contribution Expenses Allocated From Related Party
AdjustmentsToAdditionalPaidInCapitalContributionExpensesAllocatedFromRelatedParty
38000 usd
CY2021Q3 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
7669000 usd
CY2021Q3 us-gaap Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax
OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
169000 usd
CY2021Q3 us-gaap Net Income Loss
NetIncomeLoss
-37703000 usd
CY2021Q3 us-gaap Stockholders Equity
StockholdersEquity
536397000 usd
CY2021Q4 imvt Adjustments To Additional Paid In Capital Contribution Share Based Compensation
AdjustmentsToAdditionalPaidInCapitalContributionShareBasedCompensation
205000 usd
CY2021Q4 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
9954000 usd
CY2021Q4 us-gaap Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax
OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
-23000 usd
CY2021Q4 us-gaap Net Income Loss
NetIncomeLoss
-41385000 usd
CY2021Q4 us-gaap Stockholders Equity
StockholdersEquity
505148000 usd
us-gaap Net Income Loss
NetIncomeLoss
-151528000 usd
us-gaap Net Income Loss
NetIncomeLoss
-109559000 usd
us-gaap Share Based Compensation
ShareBasedCompensation
24750000 usd
us-gaap Depreciation
Depreciation
139000 usd
us-gaap Depreciation
Depreciation
87000 usd
us-gaap Operating Lease Right Of Use Asset Amortization Expense
OperatingLeaseRightOfUseAssetAmortizationExpense
844000 usd
us-gaap Operating Lease Right Of Use Asset Amortization Expense
OperatingLeaseRightOfUseAssetAmortizationExpense
831000 usd
us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
-11762000 usd
us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
7918000 usd
us-gaap Increase Decrease In Prepaid Expense
IncreaseDecreaseInPrepaidExpense
14297000 usd
us-gaap Increase Decrease In Prepaid Expense
IncreaseDecreaseInPrepaidExpense
-4109000 usd
us-gaap Increase Decrease In Accounts Payable Trade
IncreaseDecreaseInAccountsPayableTrade
-4495000 usd
us-gaap Increase Decrease In Accounts Payable Trade
IncreaseDecreaseInAccountsPayableTrade
1383000 usd
us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
1278000 usd
us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
16188000 usd
us-gaap Increase Decrease In Operating Lease Liability
IncreaseDecreaseInOperatingLeaseLiability
-853000 usd
us-gaap Increase Decrease In Operating Lease Liability
IncreaseDecreaseInOperatingLeaseLiability
-658000 usd
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-132400000 usd
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-73156000 usd
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
171000 usd
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
136000 usd
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-171000 usd
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-136000 usd
us-gaap Payments Of Stock Issuance Costs
PaymentsOfStockIssuanceCosts
272000 usd
us-gaap Payments Of Stock Issuance Costs
PaymentsOfStockIssuanceCosts
0 usd
us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
424000 usd
us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
0 usd
us-gaap Proceeds From Contributed Capital
ProceedsFromContributedCapital
0 usd
us-gaap Proceeds From Contributed Capital
ProceedsFromContributedCapital
129000 usd
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
70652000 usd
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
200129000 usd
us-gaap Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
710000 usd
us-gaap Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
20000 usd
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
-61209000 usd
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
126857000 usd
CY2022Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
493817000 usd
CY2021Q4 imvt Adjustments To Additional Paid In Capital Contribution Expenses Allocated From Related Party
AdjustmentsToAdditionalPaidInCapitalContributionExpensesAllocatedFromRelatedParty
0 usd
CY2021Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
400146000 usd
CY2022Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
432608000 usd
CY2021Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
527003000 usd
us-gaap Number Of Operating Segments
NumberOfOperatingSegments
1 segment
us-gaap Number Of Reportable Segments
NumberOfReportableSegments
1 segment
CY2022Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
432600000 usd
CY2022Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-506900000 usd
us-gaap Use Of Estimates
UseOfEstimates
<div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">[B] Use of Estimates</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The preparation of unaudited condensed consolidated financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the amounts reported in the unaudited condensed consolidated financial statements and accompanying notes. The Company regularly evaluates estimates and assumptions related to assets, liabilities, stock-based compensation, litigation accruals, clinical trial accruals, operating leases, research and development costs and income taxes. The Company bases its estimates and assumptions on historical experience and on various other factors that it believes to be reasonable under the circumstances, the results of which form the basis for making judgments about the carrying values of assets and liabilities that are not readily apparent from other sources. Actual results could differ from those estimates.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Additionally, the Company assessed the impact that the COVID-19 pandemic, geopolitical tensions and resulting global slowdown of economic activity, decades-high inflation, rising interest rates and a potential recession in the U.S. has had on its operations and financial results as of December 31, 2022 and through the issuance of these unaudited condensed consolidated financial statements. The Company’s analysis was informed by the facts and circumstances as they were known to the Company. This assessment considered the impact that these uncertainties may have on financial estimates and assumptions that affect the reported amounts of assets and liabilities and expenses.</span></div>
CY2022Q4 us-gaap Related Party Transaction Amounts Of Transaction
RelatedPartyTransactionAmountsOfTransaction
0 usd
us-gaap Concentration Risk Credit Risk
ConcentrationRiskCreditRisk
<div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">[D] Concentration of Credit Risk</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Financial instruments that potentially subject the Company to concentration of credit risk include cash and cash equivalents. As of December 31, 2022, the cash and cash equivalents balance is kept in banking institutions that the Company believes are of high credit quality and are in excess of federally insured levels. The Company maintains its cash and cash equivalents with accredited financial institutions and accordingly, such funds are subject to minimal credit risk. The Company has not experienced any losses on its cash and cash equivalents.</span></div>
CY2022Q1 us-gaap Cash Equivalents At Carrying Value
CashEquivalentsAtCarryingValue
0 usd
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
0
us-gaap Related Party Transaction Amounts Of Transaction
RelatedPartyTransactionAmountsOfTransaction
400000 usd
CY2021Q4 us-gaap Related Party Transaction Amounts Of Transaction
RelatedPartyTransactionAmountsOfTransaction
200000 usd
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
15816056 shares
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
10250385 shares
CY2017Q4 imvt Upfront Payments
UpfrontPayments
30000000.0 usd
CY2017Q4 imvt Percentage Of Research And Development Costs
PercentageOfResearchAndDevelopmentCosts
0.50
CY2022Q4 imvt Cumulative Milestone Payments
CumulativeMilestonePayments
20000000.0 usd
CY2018Q4 imvt Sub Licensed Agreement Aggregate Purchase Price
SubLicensedAgreementAggregatePurchasePrice
37800000 usd
CY2022Q4 imvt Milestone Payments
MilestonePayments
10000000.0 usd
CY2022Q4 imvt Accrued Research And Development Expenses
AccruedResearchAndDevelopmentExpenses
18220000 usd
CY2022Q1 imvt Accrued Research And Development Expenses
AccruedResearchAndDevelopmentExpenses
18196000 usd
CY2022Q4 us-gaap Accrued Bonuses Current
AccruedBonusesCurrent
5345000 usd
CY2022Q1 us-gaap Accrued Bonuses Current
AccruedBonusesCurrent
4456000 usd
CY2022Q4 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
283000 usd
CY2022Q1 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
679000 usd
CY2022Q4 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
2202000 usd
CY2022Q1 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
1415000 usd
CY2022Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
26050000 usd
CY2022Q1 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
24746000 usd
imvt Adjustments To Additional Paid In Capital Contribution Expenses Allocated From Related Party
AdjustmentsToAdditionalPaidInCapitalContributionExpensesAllocatedFromRelatedParty
100000 usd
CY2020Q2 imvt Number Of Sublease Agreements
NumberOfSubleaseAgreements
2 subleaseagreement
CY2022Q4 us-gaap Operating Lease Expense
OperatingLeaseExpense
300000 usd
CY2021Q4 us-gaap Operating Lease Expense
OperatingLeaseExpense
300000 usd
us-gaap Operating Lease Expense
OperatingLeaseExpense
900000 usd
us-gaap Operating Lease Expense
OperatingLeaseExpense
900000 usd
CY2022Q4 us-gaap Effective Income Tax Rate Continuing Operations
EffectiveIncomeTaxRateContinuingOperations
-0.0062
CY2021Q4 us-gaap Effective Income Tax Rate Continuing Operations
EffectiveIncomeTaxRateContinuingOperations
0
us-gaap Effective Income Tax Rate Continuing Operations
EffectiveIncomeTaxRateContinuingOperations
0.0007
CY2022Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.0001
CY2022Q4 us-gaap Sale Of Stock Price Per Share
SaleOfStockPricePerShare
6.00
CY2022Q4 us-gaap Sale Of Stock Consideration Received On Transaction
SaleOfStockConsiderationReceivedOnTransaction
70200000 usd
CY2022Q4 us-gaap Convertible Preferred Stock Shares Reserved For Future Issuance
ConvertiblePreferredStockSharesReservedForFutureIssuance
10000 shares
CY2022Q1 us-gaap Convertible Preferred Stock Shares Reserved For Future Issuance
ConvertiblePreferredStockSharesReservedForFutureIssuance
10000 shares
CY2022Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
11277282 shares
CY2022Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
8018731 shares
CY2022Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Number Of Shares Available For Grant
ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant
1286372 shares
CY2022Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Number Of Shares Available For Grant
ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant
2188860 shares
CY2022Q4 us-gaap Common Stock Capital Shares Reserved For Future Issuance
CommonStockCapitalSharesReservedForFutureIssuance
17410189 shares
CY2022Q1 us-gaap Common Stock Capital Shares Reserved For Future Issuance
CommonStockCapitalSharesReservedForFutureIssuance
13033788 shares
CY2022Q2 us-gaap Common Stock Capital Shares Reserved For Future Issuance
CommonStockCapitalSharesReservedForFutureIssuance
4659315 shares
CY2022Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
8018731 shares
CY2022Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
8.48
CY2022Q2 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
P8Y6M7D
CY2022Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
60000 usd
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
3622676 shares
us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
5.60
us-gaap Stock Issued During Period Shares Stock Options Exercised
StockIssuedDuringPeriodSharesStockOptionsExercised
57678 shares
us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
7.35
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod
275038 shares
us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Forfeitures In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice
6.31
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Expirations In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod
31409 shares
us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Expirations In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice
8.69
CY2022Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
11277282 shares
CY2022Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
7.61
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
P8Y4M2D
CY2022Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
114573000 usd
CY2022Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
4607462 shares
CY2022Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice
8.86
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Weighted Average Remaining Contractual Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1
P7Y3M10D
CY2022Q4 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Intrinsic Value1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1
41192000 usd
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercises In Period Total Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue
200000 usd
us-gaap Stock Issued During Period Shares Stock Options Exercised
StockIssuedDuringPeriodSharesStockOptionsExercised
0 shares
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
4.22
CY2022Q4 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
P6Y1M9D
CY2021Q4 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
P6Y1M9D
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
P6Y1M9D
CY2022Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
0
CY2021Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
0
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
0
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
0
CY2022Q4 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
8856000 usd
CY2021Q4 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
9954000 usd
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
24462000 usd
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
21443000 usd

Files In Submission

Name View Source Status
0001764013-23-000022-index-headers.html Edgar Link pending
0001764013-23-000022-index.html Edgar Link pending
0001764013-23-000022.txt Edgar Link pending
0001764013-23-000022-xbrl.zip Edgar Link pending
exhibit101-20221231q3.htm Edgar Link pending
exhibit102-20221231q3.htm Edgar Link pending
exhibit103-20221231q3.htm Edgar Link pending
exhibit104-20221231q3.htm Edgar Link pending
exhibit105-20221231q3.htm Edgar Link pending
exhibit106-20221231q3.htm Edgar Link pending
exhibit311-20221231q3.htm Edgar Link pending
exhibit312-20221231q3.htm Edgar Link pending
exhibit321-20221231q3.htm Edgar Link pending
exhibit322-20221231q3.htm Edgar Link pending
Financial_Report.xlsx Edgar Link pending
imvt-20221231.htm Edgar Link pending
imvt-20221231.xsd Edgar Link pending
MetaLinks.json Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
FilingSummary.xml Edgar Link unprocessable
imvt-20221231_lab.xml Edgar Link unprocessable
imvt-20221231_pre.xml Edgar Link unprocessable
imvt-20221231_cal.xml Edgar Link unprocessable
imvt-20221231_def.xml Edgar Link unprocessable
imvt-20221231_htm.xml Edgar Link completed
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R4.htm Edgar Link pending
R5.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending